Lido Advisors
VAXX

Lido Advisors’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Lido Advisors’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,824
Closed -$19.4K – 1268
2022
Q4 		$19.4K Hold
13,824
– – ﹤0.01% 1010
2022
Q3 		$27K Hold
13,824
– – ﹤0.01% 929
2022
Q2 		$21K Buy
+13,824
New +$52.3K ﹤0.01% 920

Other funds holding VAXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Lido Advisors's VAXX Position: Q1 2023 in Review

Lido Advisors sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q1 2023, closing a stake of 13,824 shares — an estimated $19.4K sold.

Lido Advisors first reported a position in VAXX in Q2 2022 and held it in 3 quarters. The position peaked at $27K in Q3 2022. 48 funds tracked by Wall St. Rank hold VAXX as of Q1 2023.

  • Lido Advisors reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Lido Advisors sold 13,824 Vaxxinity, Inc. Class A Common Stock shares in Q1 2023, an estimated $19.4K.
  • Lido Advisors first reported a position in Vaxxinity, Inc. Class A Common Stock in Q2 2022 and held it in 3 quarters.
  • Lido Advisors's Vaxxinity, Inc. Class A Common Stock position peaked at $27K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q1 2023.

Based on Lido Advisors's 13F filing for Q1 2023, filed 15 May 2023.